School of Medicine
Showing 1-7 of 7 Results
-
Ryann Fame, PhD
Assistant Professor of Neurosurgery (Adult Neurosurgery)
Current Research and Scholarly InterestsEarly neural progenitors respond to extrinsic cues that maintain and support their potency. These stem/ progenitor cells are in direct contact with the cerebrospinal fluid (CSF), which acts as part of their niche. Our research program encompasses the early neural stem cell niche, neural tube closure, CSF, metabolism, and cortical neuronal development. We are dedicated to broad collaboration focused on translating an understanding of neurodevelopment and CSF biology into regenerative strategies.
-
Nielsen Fernandez-Becker
Clinical Professor, Medicine - Gastroenterology & Hepatology
BioI am the director of the Celiac Disease Program at Stanford and I am highly experienced in diagnosis and management of celiac disease and gluten associated disorders.
My objective is to provide excellent and compassionate clinical care for my patients while seeking a better understanding of diseases I treat, particularly Celiac disease (CeD), eosinophilic esophagitis (EoE). My top priorities are patient care and translational research to make new discoveries and improve the care my patients. -
Michael Fischbach
Liu (Liao) Family Professor
Current Research and Scholarly InterestsThe microbiome carries out extraordinary feats of biology: it produces hundreds of molecules, many of which impact host physiology; modulates immune function potently and specifically; self-organizes biogeographically; and exhibits profound stability in the face of perturbations. Our lab studies the mechanisms of microbiome-host interactions. Our approach is based on two technologies we recently developed: a complex (119-member) defined gut community that serves as an analytically manageable but biologically relevant system for experimentation, and new genetic systems for common species from the microbiome. Using these systems, we investigate mechanisms at the community level and the strain level.
1) Community-level mechanisms. A typical gut microbiome consists of 200-250 bacterial species that span >6 orders of magnitude in relative abundance. As a system, these bacteria carry out extraordinary feats of metabolite consumption and production, elicit a variety of specific immune cell populations, self-organize geographically and metabolically, and exhibit profound resilience against a wide range of perturbations. Yet remarkably little is known about how the community functions as a system. We are exploring this by asking two broad questions: How do groups of organisms work together to influence immune function? What are the mechanisms that govern metabolism and ecology at the 100+ strain scale? Our goal is to learn rules that will enable us to design communities that solve specific therapeutic problems.
2) Strain-level mechanisms. Even though gut and skin colonists live in communities, individual strains can have an extraordinary impact on host biology. We focus on two broad (and partially overlapping) categories:
Immune modulation: Can we redirect colonist-specific T cells against an antigen of interest by expressing it on the surface of a bacterium? How do skin colonists induce high levels of Staphylococcus-specific antibodies in mice and humans?
Abundant microbiome-derived molecules: By constructing single-strain/single-gene knockouts in a complex defined community, we will ask: What are the effects of bacterially produced molecules on host metabolism and immunology? Can the molecular output of low-abundance organisms impact host physiology?
3) Cell and gene therapy. We have begun two new efforts in mammalian cell and gene therapies. First, we are developing methods that enable cell-type specific delivery of genome editing payloads in vivo. We are especially interested in delivery vehicles that are customizable and easy to manufacture. Second, we have begun a comprehensive genome mining effort with an emphasis on understudied or entirely novel enzyme systems with utility in mammalian genome editing. -
Matilda Fresk
LSRP 2, Pediatrics - Gastroenterology
BioBiorepository Manager and Life Science Research Professional at Stanford Medicine. I support both the Center for IBD and Celiac Disease and Dr. Michael Rosen’s Lab, where my primary focus is the administration and execution of the Biorepository study.
My role bridges strategic operations with hands-on technical execution. I oversee the development of SOPs, inventory management, and maintain direct contact with our cohort of research participants and their families. I also collaborate closely with research labs across Stanford to supply them with biorepository samples, ensuring full regulatory compliance and proper documentation for all de-identified sample transfers. Furthermore, I provide integral support for our Clinical Research Coordinators (CRCs) on key initiatives, including the CAPTURE IBD and MUSIC-CD studies, managing essential processes such as visit registration, supply procurement, research kit preparation, and biospecimen processing.
I bring a deeply technical engineering background, with over three years specialized in the generation, characterization, and affinity purification of antibody-based constructs and AAV vectors, with a strong understanding of process development. Previously a Research Engineer at KTH Royal Institute of Technology, where I coordinated autoimmune research with the Karolinska Institute.
I hold both an MSc and a BSc in Medical Biotechnology from KTH Royal Institute of Technology. -
Adam Frymoyer
Clinical Professor, Pediatrics - Neonatology
Current Research and Scholarly InterestsMy research uses quantitative pharmacology and quality improvement science to improve care for neonates and children. I develop individualized, evidence-based dosing strategies and translate them into real-time clinical tools, while leading research to identify and close gaps between evidence and practice across the newborn continuum. Across both programs, my goal is to translate rigorous science into better bedside care and improve child health.
